COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon invites to conference call on the results of the first quarter of 2026 and announces participation in international investor conferences
Formycon AG invites to conference call on Q1 2026 results and announces participation in investor conferences. Key focus on biosimilars and financial outlook -
-
-
COMMUNIQUÉ DE PRESSE
Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive® and Baiama® are now available in the European Union
Formycon expands commercial portfolio with the launch of Aflibercept biosimilars Ahzantive(R) and Baiama(R) in the European Union, reinforcing market penetration and growth strategy -
-
-
COMMUNIQUÉ DE PRESSE
Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships
Formycon AG reports successful financial year 2025 with operational progress, market growth, and strategic partnerships. Forecast for 2026 includes revenue growth and positive EBITDA
